Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Anticancer therapeutics : from drug discovery to clinical applications / / Adam A. Todd, Paul W. Groundwater, Jason Gill
| Anticancer therapeutics : from drug discovery to clinical applications / / Adam A. Todd, Paul W. Groundwater, Jason Gill |
| Autore | Todd Adam A. <1982-> |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley, , 2018 |
| Descrizione fisica | 1 online resource (449 pages) : illustrations (some color) |
| Disciplina | 616.994061 |
| Soggetto topico |
Antineoplastic agents - Development
Antineoplastic agents - Design Antineoplastic agents - Therapeutic use |
| ISBN |
1-118-69620-4
1-118-69621-2 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910271017503321 |
Todd Adam A. <1982->
|
||
| Hoboken, New Jersey : , : Wiley, , 2018 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Anticancer therapeutics : from drug discovery to clinical applications / / Adam A. Todd, Paul W. Groundwater, Jason Gill
| Anticancer therapeutics : from drug discovery to clinical applications / / Adam A. Todd, Paul W. Groundwater, Jason Gill |
| Autore | Todd Adam A. <1982-> |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley, , 2018 |
| Descrizione fisica | 1 online resource (449 pages) : illustrations (some color) |
| Disciplina | 616.994061 |
| Soggetto topico |
Antineoplastic agents - Development
Antineoplastic agents - Design Antineoplastic agents - Therapeutic use |
| ISBN |
1-118-69620-4
1-118-69621-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910816143903321 |
|
Todd Adam A. <1982->
|
||
| Hoboken, New Jersey : , : Wiley, , 2018 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer drug design and discovery [[electronic resource] /] / Stephen Neidle
| Cancer drug design and discovery [[electronic resource] /] / Stephen Neidle |
| Autore | Neidle Stephen |
| Pubbl/distr/stampa | London, : Academic, c2008 |
| Descrizione fisica | 1 online resource (517 p.) |
| Disciplina | 616.994061 |
| Soggetto topico |
Antineoplastic agents - Development
Antineoplastic agents - Design |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-281-76368-3
9786611763688 0-08-055495-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Cancer Drug Design and Discovery; Copyright Page; Contents; About the editor; Contributors; Introduction; PART I: BASIC PRINCIPLES; Chapter 1 Modern cancer drug discovery: integrating targets, technologies and treatments; 1.1 Introduction: changing times; 1.2 Successes and limitations; 1.3 Integrated small-molecule drug discovery and development; 1.4 New molecular targets: the ""druggable"" cancer genome; 1.5 From drug target to development candidate; 1.6 Examples of case histories for molecularly targeted cancer therapeutics
1.7 Biomarkers, the pharmacological audit trail and clinical development1.8 Conclusions and outlook: towards individualized molecular cancer medicine; References; Chapter 2 Preclinical pharmacology and in vivo models; 2.1 Introduction; 2.2 Contemporary preclinical cancer drug discovery; 2.3 In vitro pharmacological evaluation; 2.4 Information gained from in vitro cell lines; 2.5 In vivo pharmacokinetics (PK) and pharmacodynamics (PD): continuing the pharmacological audit trail; 2.6 In vivo anti-tumor models: choice and predictiveness?; 2.7 Concluding remarks; References Chapter 3 Clinical trial designs for more rapid proof-of-principle and approval3.1 Introduction; 3.2 NDA plan at the time of IND; 3.3 Phase I trial design innovations; 3.4 Concept of a continuous Phase I; 3.5 Phase II trial design innovations; 3.6 Phase III trial design innovations (enrichment designs); 3.7 Other approaches to enrich trial populations; 3.8 Innovations in design and selection of endpoints; 3.9 Regulatory strategies; 3.10 Other approaches to accelerate drug development; 3.11 New perspectives; 3.12 Summary; References; PART II: METHODOLOGY Chapter 4 Structural biology and anticancer drug design4.1 Introduction; 4.2 High-throughput X-ray crystallography; 4.3 Structural biology and structure-based drug design; 4.4 Fragment screening using X-ray crystallography; 4.5 Case history: cyclin-dependent kinase inhibitors, from fragment hit to clinical candidate; 4.6 Compound profiling; 4.7 Conclusions; References; Chapter 5 Natural product chemistry and anticancer drug discovery; 5.1 Introduction; 5.2 Exemestane (aromasin); 5.3 Fulvestrant/faslodex; 5.4 Flavonoids; 5.5 Bexarotene (targretin); 5.6 Epothilones; 5.7 Maytansine 5.8 Geldanamycin5.9 UCN-01; 5.10 Camptothecin; 5.11 Prodigiosin; 5.12 Azacitidine; 5.13 FK-288; 5.14 Hemiasterlin; 5.15 Calicheamicin; 5.16 Conclusion; References; Chapter 6 Pharmacokinetics and ADME optimization in drug discovery; 6.1 Introduction; 6.2 Absorption; 6.3 Distribution; 6.4 Metabolism; 6.5 Elimination; 6.6 Biochemical barriers to drug therapy: efflux transporters; 6.7 Induction; 6.8 Conclusions; References; PART III: DRUGS IN THE CLINIC; Chapter 7 Temozolomide: from cytotoxic to molecularly-targeted agent; 7.1 Introduction 7.2 Towards imidazotetrazines and azolastone (mitozolomide) |
| Record Nr. | UNINA-9910451715203321 |
|
Neidle Stephen
|
||
| London, : Academic, c2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer drug design and discovery / / Stephen Neidle
| Cancer drug design and discovery / / Stephen Neidle |
| Autore | Neidle Stephen |
| Pubbl/distr/stampa | London, : Academic, c2008 |
| Descrizione fisica | 1 online resource (517 pages) |
| Disciplina | 616.994061 |
| Soggetto topico |
Antineoplastic agents - Development
Antineoplastic agents - Design |
| ISBN |
1-281-76368-3
9786611763688 0-08-055495-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Cancer Drug Design and Discovery; Copyright Page; Contents; About the editor; Contributors; Introduction; PART I: BASIC PRINCIPLES; Chapter 1 Modern cancer drug discovery: integrating targets, technologies and treatments; 1.1 Introduction: changing times; 1.2 Successes and limitations; 1.3 Integrated small-molecule drug discovery and development; 1.4 New molecular targets: the ""druggable"" cancer genome; 1.5 From drug target to development candidate; 1.6 Examples of case histories for molecularly targeted cancer therapeutics
1.7 Biomarkers, the pharmacological audit trail and clinical development; 1.8 Conclusions and outlook: towards individualized molecular cancer medicine; References; Chapter 2 Preclinical pharmacology and in vivo models; 2.1 Introduction; 2.2 Contemporary preclinical cancer drug discovery; 2.3 In vitro pharmacological evaluation; 2.4 Information gained from in vitro cell lines; 2.5 In vivo pharmacokinetics (PK) and pharmacodynamics (PD): continuing the pharmacological audit trail; 2.6 In vivo anti-tumor models: choice and predictiveness?; 2.7 Concluding remarks; References Chapter 3 Clinical trial designs for more rapid proof-of-principle and approval; 3.1 Introduction; 3.2 NDA plan at the time of IND; 3.3 Phase I trial design innovations; 3.4 Concept of a continuous Phase I; 3.5 Phase II trial design innovations; 3.6 Phase III trial design innovations (enrichment designs); 3.7 Other approaches to enrich trial populations; 3.8 Innovations in design and selection of endpoints; 3.9 Regulatory strategies; 3.10 Other approaches to accelerate drug development; 3.11 New perspectives; 3.12 Summary; References; PART II: METHODOLOGY Chapter 4 Structural biology and anticancer drug design; 4.1 Introduction; 4.2 High-throughput X-ray crystallography; 4.3 Structural biology and structure-based drug design; 4.4 Fragment screening using X-ray crystallography; 4.5 Case history: cyclin-dependent kinase inhibitors, from fragment hit to clinical candidate; 4.6 Compound profiling; 4.7 Conclusions; References; Chapter 5 Natural product chemistry and anticancer drug discovery; 5.1 Introduction; 5.2 Exemestane (aromasin); 5.3 Fulvestrant/faslodex; 5.4 Flavonoids; 5.5 Bexarotene (targretin); 5.6 Epothilones; 5.7 Maytansine 5.8 Geldanamycin; 5.9 UCN-01; 5.10 Camptothecin; 5.11 Prodigiosin; 5.12 Azacitidine; 5.13 FK-288; 5.14 Hemiasterlin; 5.15 Calicheamicin; 5.16 Conclusion; References; Chapter 6 Pharmacokinetics and ADME optimization in drug discovery; 6.1 Introduction; 6.2 Absorption; 6.3 Distribution; 6.4 Metabolism; 6.5 Elimination; 6.6 Biochemical barriers to drug therapy: efflux transporters; 6.7 Induction; 6.8 Conclusions; References; PART III: DRUGS IN THE CLINIC; Chapter 7 Temozolomide: from cytotoxic to molecularly-targeted agent; 7.1 Introduction; 7.2 Towards imidazotetrazines and azolastone (mitozolomide) |
| Record Nr. | UNINA-9910781802303321 |
|
Neidle Stephen
|
||
| London, : Academic, c2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer drug design and discovery / / Stephen Neidle
| Cancer drug design and discovery / / Stephen Neidle |
| Autore | Neidle Stephen |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | London, : Academic, c2008 |
| Descrizione fisica | 1 online resource (517 pages) |
| Disciplina | 616.994061 |
| Soggetto topico |
Antineoplastic agents - Development
Antineoplastic agents - Design |
| ISBN |
1-281-76368-3
9786611763688 0-08-055495-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Cancer Drug Design and Discovery; Copyright Page; Contents; About the editor; Contributors; Introduction; PART I: BASIC PRINCIPLES; Chapter 1 Modern cancer drug discovery: integrating targets, technologies and treatments; 1.1 Introduction: changing times; 1.2 Successes and limitations; 1.3 Integrated small-molecule drug discovery and development; 1.4 New molecular targets: the ""druggable"" cancer genome; 1.5 From drug target to development candidate; 1.6 Examples of case histories for molecularly targeted cancer therapeutics
1.7 Biomarkers, the pharmacological audit trail and clinical development; 1.8 Conclusions and outlook: towards individualized molecular cancer medicine; References; Chapter 2 Preclinical pharmacology and in vivo models; 2.1 Introduction; 2.2 Contemporary preclinical cancer drug discovery; 2.3 In vitro pharmacological evaluation; 2.4 Information gained from in vitro cell lines; 2.5 In vivo pharmacokinetics (PK) and pharmacodynamics (PD): continuing the pharmacological audit trail; 2.6 In vivo anti-tumor models: choice and predictiveness?; 2.7 Concluding remarks; References Chapter 3 Clinical trial designs for more rapid proof-of-principle and approval; 3.1 Introduction; 3.2 NDA plan at the time of IND; 3.3 Phase I trial design innovations; 3.4 Concept of a continuous Phase I; 3.5 Phase II trial design innovations; 3.6 Phase III trial design innovations (enrichment designs); 3.7 Other approaches to enrich trial populations; 3.8 Innovations in design and selection of endpoints; 3.9 Regulatory strategies; 3.10 Other approaches to accelerate drug development; 3.11 New perspectives; 3.12 Summary; References; PART II: METHODOLOGY Chapter 4 Structural biology and anticancer drug design; 4.1 Introduction; 4.2 High-throughput X-ray crystallography; 4.3 Structural biology and structure-based drug design; 4.4 Fragment screening using X-ray crystallography; 4.5 Case history: cyclin-dependent kinase inhibitors, from fragment hit to clinical candidate; 4.6 Compound profiling; 4.7 Conclusions; References; Chapter 5 Natural product chemistry and anticancer drug discovery; 5.1 Introduction; 5.2 Exemestane (aromasin); 5.3 Fulvestrant/faslodex; 5.4 Flavonoids; 5.5 Bexarotene (targretin); 5.6 Epothilones; 5.7 Maytansine 5.8 Geldanamycin; 5.9 UCN-01; 5.10 Camptothecin; 5.11 Prodigiosin; 5.12 Azacitidine; 5.13 FK-288; 5.14 Hemiasterlin; 5.15 Calicheamicin; 5.16 Conclusion; References; Chapter 6 Pharmacokinetics and ADME optimization in drug discovery; 6.1 Introduction; 6.2 Absorption; 6.3 Distribution; 6.4 Metabolism; 6.5 Elimination; 6.6 Biochemical barriers to drug therapy: efflux transporters; 6.7 Induction; 6.8 Conclusions; References; PART III: DRUGS IN THE CLINIC; Chapter 7 Temozolomide: from cytotoxic to molecularly-targeted agent; 7.1 Introduction; 7.2 Towards imidazotetrazines and azolastone (mitozolomide) |
| Record Nr. | UNINA-9910825084803321 |
|
Neidle Stephen
|
||
| London, : Academic, c2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Federal agency roles in cancer drug development from preclinical research to new drug approval [[electronic resource] ] : the National Cancer Institute and the Food and Drug Administration / / Joseph P. Newhouse, John Mendelsohn, Hellen Gelband and Roger Herdman
| Federal agency roles in cancer drug development from preclinical research to new drug approval [[electronic resource] ] : the National Cancer Institute and the Food and Drug Administration / / Joseph P. Newhouse, John Mendelsohn, Hellen Gelband and Roger Herdman |
| Autore | Newhouse Joseph P |
| Edizione | [3rd ed.] |
| Pubbl/distr/stampa | Washington, D.C., : National Academy Press, c2005 |
| Descrizione fisica | 1 online resource (69 p.) |
| Altri autori (Persone) |
MendelsohnJohn M
GelbandHellen HerdmanRoger |
| Soggetto topico |
Antineoplastic agents - Development
Public administration - United States |
| Soggetto genere / forma | Electronic books. |
| ISBN | 0-309-54976-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | ""FRONT MATTER""; ""Table of Contents""; ""1 SCIENTIFIC RATIONALE""; ""2 THE NATIONAL CANCER INSTITUTE""; ""3 THE FOOD AND DRUG ADMINISTRATION""; ""4 SUMMARY: THE ROLES OF THE NCI AND FDA IN DEVELOPING ANTICANCER AGENTS""; ""REFERENCES""; ""ACRONYMS AND ABBREVIATIONS"" |
| Record Nr. | UNINA-9910450324403321 |
|
Newhouse Joseph P
|
||
| Washington, D.C., : National Academy Press, c2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Federal agency roles in cancer drug development from preclinical research to new drug approval [[electronic resource] ] : the National Cancer Institute and the Food and Drug Administration / / Joseph P. Newhouse, John Mendelsohn, Hellen Gelband and Roger Herdman
| Federal agency roles in cancer drug development from preclinical research to new drug approval [[electronic resource] ] : the National Cancer Institute and the Food and Drug Administration / / Joseph P. Newhouse, John Mendelsohn, Hellen Gelband and Roger Herdman |
| Autore | Newhouse Joseph P |
| Edizione | [3rd ed.] |
| Pubbl/distr/stampa | Washington, D.C., : National Academy Press, c2005 |
| Descrizione fisica | 1 online resource (69 p.) |
| Altri autori (Persone) |
MendelsohnJohn M
GelbandHellen HerdmanRoger |
| Soggetto topico |
Antineoplastic agents - Development
Public administration - United States |
| ISBN | 0-309-54976-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | ""FRONT MATTER""; ""Table of Contents""; ""1 SCIENTIFIC RATIONALE""; ""2 THE NATIONAL CANCER INSTITUTE""; ""3 THE FOOD AND DRUG ADMINISTRATION""; ""4 SUMMARY: THE ROLES OF THE NCI AND FDA IN DEVELOPING ANTICANCER AGENTS""; ""REFERENCES""; ""ACRONYMS AND ABBREVIATIONS"" |
| Record Nr. | UNINA-9910783331003321 |
|
Newhouse Joseph P
|
||
| Washington, D.C., : National Academy Press, c2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Federal agency roles in cancer drug development from preclinical research to new drug approval : the National Cancer Institute and the Food and Drug Administration / / Joseph P. Newhouse, John Mendelsohn, Hellen Gelband and Roger Herdman
| Federal agency roles in cancer drug development from preclinical research to new drug approval : the National Cancer Institute and the Food and Drug Administration / / Joseph P. Newhouse, John Mendelsohn, Hellen Gelband and Roger Herdman |
| Autore | Newhouse Joseph P |
| Edizione | [3rd ed.] |
| Pubbl/distr/stampa | Washington, D.C., : National Academy Press, c2005 |
| Descrizione fisica | 1 online resource (69 p.) |
| Altri autori (Persone) |
MendelsohnJohn M
GelbandHellen HerdmanRoger |
| Soggetto topico |
Antineoplastic agents - Development
Public administration - United States |
| ISBN | 0-309-54976-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | ""FRONT MATTER""; ""Table of Contents""; ""1 SCIENTIFIC RATIONALE""; ""2 THE NATIONAL CANCER INSTITUTE""; ""3 THE FOOD AND DRUG ADMINISTRATION""; ""4 SUMMARY: THE ROLES OF THE NCI AND FDA IN DEVELOPING ANTICANCER AGENTS""; ""REFERENCES""; ""ACRONYMS AND ABBREVIATIONS"" |
| Record Nr. | UNINA-9910821185703321 |
|
Newhouse Joseph P
|
||
| Washington, D.C., : National Academy Press, c2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Molecular cancer therapeutics : strategies for drug discovery and development
| Molecular cancer therapeutics : strategies for drug discovery and development |
| Pubbl/distr/stampa | [Place of publication not identified], : Wiley Liss, 2004 |
| Descrizione fisica | 1 online resource (362 pages) |
| Disciplina | 616.99/4061 |
| Soggetto topico |
Cancer - Chemotherapy
Cancer - Immunotherapy Antineoplastic agents - Development Pharmacogenetics Antineoplastic Agents Drug Delivery Systems Drug Evaluation Neoplasms Drug Therapy Evaluation Studies as Topic Therapeutic Uses Diseases Pharmacology Genetics Investigative Techniques Pharmacologic Actions Therapeutics Biology Health Occupations Biological Science Disciplines Chemical Actions and Uses Analytical, Diagnostic and Therapeutic Techniques and Equipment Natural Science Disciplines Disciplines and Occupations Chemicals and Drugs Oncology Medicine Health & Biological Sciences |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-55673-0
9786610556731 0-471-65615-1 0-471-65616-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910146065303321 |
| [Place of publication not identified], : Wiley Liss, 2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Molecular cancer therapeutics : strategies for drug discovery and development
| Molecular cancer therapeutics : strategies for drug discovery and development |
| Pubbl/distr/stampa | [Place of publication not identified], : Wiley Liss, 2004 |
| Descrizione fisica | 1 online resource (362 pages) |
| Disciplina | 616.99/4061 |
| Soggetto topico |
Cancer - Chemotherapy
Cancer - Immunotherapy Antineoplastic agents - Development Pharmacogenetics Antineoplastic Agents Drug Delivery Systems Drug Evaluation Neoplasms Drug Therapy Evaluation Studies as Topic Therapeutic Uses Diseases Pharmacology Genetics Investigative Techniques Pharmacologic Actions Therapeutics Biology Health Occupations Biological Science Disciplines Chemical Actions and Uses Analytical, Diagnostic and Therapeutic Techniques and Equipment Natural Science Disciplines Disciplines and Occupations Chemicals and Drugs Oncology Medicine Health & Biological Sciences |
| ISBN |
1-280-55673-0
9786610556731 0-471-65615-1 0-471-65616-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910830570703321 |
| [Place of publication not identified], : Wiley Liss, 2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
